Finally, PET/MR applications in 4Is cardiovascular diseases are also briefly described. Whilst these novel tracers are currently mainly applied in early clinical trials, some multicenter trials are underway and we foresee in the near future their use in clinical care and inclusion in the clinical guidelines. A major focus is put on procedures using FDG, but 4Is PET radiopharmaceuticals beyond FDG are also described in this document. This standard should be applied in clinical practice and integrated in clinical (multicenter) trials for optimal procedural standardization. With this document, we provide a standard for PET/(diagnostic) CT imaging procedures in cardiovascular diseases that are inflammatory, infective, infiltrative, or associated with dysfunctional innervation (4Is).
0 kommentar(er)
